Results from a phase I trial at Memorial Sloan Kettering Cancer Center suggest that treatment with mRNA vaccines (autogene cevumeran) cause an effective and lasting immune response in some patients with pancreatic cancer.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe